The Reformulary Group Inc. is launching the Cannabis Standard, an evidence-based medical marijuana formulary and research platform that operates on a subscription basis.
It determines if patients are a good candidate for medical cannabis based on research, reviews, clinical evidence and the advice of an expert committee. The Cannabis Standard will allow employers to access evidence and expert advice on providing coverage in their benefits plans, as well as comparative drug information.
The Reformulary Group, which announced its plan for a medical cannabis formulary in May 2018, has developed partnerships with licensed producers Canopy Growth Corp., MedReleaf Corp., Aphria Inc. and Starseed Medicinal Inc. These relationships allow it to provide employers and plan members subscribed to its platform with medical cannabis products at preferred pricing and access to customer care programs.
“Although a number of companies are not ready to add medical cannabis to their benefits plans at this time, there is a growing need for employers to offer some form of support to employees who are medical cannabis patients,” said Alison McMahon, chief executive officer of Cannabis at Work, in a press release. “Employers who secure access to preferred pricing from multiple cannabis producers, as well as medical guidance for their employees, can provide a valuable benefit to their workforce.”